Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000593844 | SCV000703969 | uncertain significance | not provided | 2017-01-04 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001243794 | SCV001416977 | likely benign | Nemaline myopathy 2 | 2024-01-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004024749 | SCV004980087 | uncertain significance | Inborn genetic diseases | 2023-10-20 | criteria provided, single submitter | clinical testing | The c.15229A>G (p.I5077V) alteration is located in exon 106 (coding exon 104) of the NEB gene. This alteration results from a A to G substitution at nucleotide position 15229, causing the isoleucine (I) at amino acid position 5077 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001243794 | SCV002084090 | uncertain significance | Nemaline myopathy 2 | 2019-11-11 | no assertion criteria provided | clinical testing |